Litcius/Paper detail

Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib

Robert Galvin, Adrienne L. Watson, David A. Largaespada, Nancy Ratner, Sara H. Osum, Christopher L. Moertel

2021Current Oncology Reports31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSelumetinibNeurofibromatosisMEK inhibitorTargeted therapyPrecision medicineNeurofibromaNeurofibromin 1OncologyInternal medicineCancer researchMAPK/ERK pathwayPathologyCancerKinaseKRASCell biologyColorectal cancerBiologyNeurofibromatosis and Schwannoma CasesSarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments